spacer gif spacer gif spacer gif spacer gif spacer gif
 QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search    

The fully linked HTML version of this article has now been published.
JCS ePress online publication date 17 Oct 2006
doi: 10.1242/jcs.03228


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcs.03228v1
119/21/4486    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calzolari, A.
Right arrow Articles by Testa, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calzolari, A.
Right arrow Articles by Testa, U.

Research Article

TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway


Alessia Calzolari, Carla Raggi, Silvia Deaglio, Nadia Maria Sposi, Marit Stafsnes, Katia Fecchi, Isabella Parolini, Fabio Malavasi, Cesare Peschle, Massimo Sargiacomo, and Ugo Testa*
* Author for correspondence (e-mail: u.testa{at}iss.it)

Transferrin receptor 2 (TfR2) possesses a YQRV motif similar to the YTRF motif of transferrin receptor 1 (TfR1) responsible for the internalization and secretion through the endosomal pathway. Raft biochemical dissection showed that TfR2 is a component of the low-density Triton-insoluble (LDTI) plasma membrane domain, able to co-immunoprecipitate with caveolin-1 and CD81, two structural raft proteins. In addition, subcellular fractionation experiments showed that TfR1, which spontaneously undergoes endocytosis and recycling, largely distributed to intracellular organelles, whereas TfR2 was mainly associated with the plasma membrane. Given the TfR2 localization in lipid rafts, we tested its capability to activate cell signalling. Interaction with an anti-TfR2 antibody or with human or bovine holotransferrin showed that it activated ERK1/ERK2 and p38 MAP kinases. Integrity of lipid rafts was required for MAPK activation. Co-localization of TfR2 with CD81, a raft tetraspanin exported through exosomes, prompted us to investigate exosomes released by HepG2 and K562 cells into culture medium. TfR2, CD81 and to a lesser extent caveolin-1, were found to be part of the exosomal budding vesicles. In conclusion, the present study indicates that TfR2 localizes in LDTI microdomains, where it promotes cell signalling, and is exported out of the cells through the exosome pathway, where it acts as an intercellular messenger.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
A. Islam, H. Jones, T. Hiroi, J. Lam, J. Zhang, J. Moss, M. Vaughan, and S. J. Levine
cAMP-dependent Protein Kinase A (PKA) Signaling Induces TNFR1 Exosome-like Vesicle Release via Anchoring of PKA Regulatory Subunit RII{beta} to BIG2
J. Biol. Chem., September 12, 2008; 283(37): 25364 - 25371.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. L. Sprague, B. D. Elzey, S. A. Crist, T. J. Waldschmidt, R. J. Jensen, and T. L. Ratliff
Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles
Blood, May 15, 2008; 111(10): 5028 - 5036.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
D. F. Wallace, L. Summerville, E. M. Crampton, and V. N. Subramaniam
Defective trafficking and localization of mutated transferrin receptor 2: implications for type 3 hereditary hemochromatosis
Am J Physiol Cell Physiol, February 1, 2008; 294(2): C383 - C390.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Valenti, V. Huber, M. Iero, P. Filipazzi, G. Parmiani, and L. Rivoltini
Tumor-Released Microvesicles as Vehicles of Immunosuppression
Cancer Res., April 1, 2007; 67(7): 2912 - 2915.
[Abstract] [Full Text] [PDF]




© The Company of Biologists Ltd 2006